[144] OptimizeRx Corporation SEC Filing

Rhea-AI Filing Summary

OptimizeRx Corporation (OPRX) notice reports a proposed sale under Rule 144 of 11,120 shares of common stock, with an aggregate market value of $198,000. The filing identifies the broker as Merrill, 80 South 8th Street, Minneapolis, MN, and lists the approximate date of sale as 08/28/2025 on Nasdaq. The shares were acquired through a series of restricted stock awards from OptimizeRx between March 31, 2019 and March 31, 2020, with vesting/payment dates shown in 2019–2020. The filer states there were no securities sold in the past three months and certifies no undisclosed material adverse information is known.

Positive

• Disclosure of proposed sale complies with Rule 144, including broker, share count, aggregate value, and acquisition/vesting history
• Securities originated from restricted stock awards with documented acquisition and vesting dates (2019–2020), providing clear provenance

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice disclosing sale of restricted shares via broker on Nasdaq; appears compliant and non-material to capitalization.

The filing documents a proposed public sale of 11,120 common shares valued at $198,000 through Merrill with an approximate sale date of 08/28/2025. Acquisition history shows these shares originated from restricted stock awards received in 2019–2020 and subsequently vested. The filer confirms no sales in the prior three months and attests to absence of undisclosed material adverse information. From a compliance standpoint the form contains the standard elements required under Rule 144: broker, number of shares, acquisition dates and nature, and vesting/payment details.

Equity Research Associate

TL;DR: Disclosure is informational and unlikely to affect market given the small size relative to outstanding shares.

The proposed sale equals roughly 0.06% of the reported 18,565,033 shares outstanding, suggesting limited market impact. The shares stem from prior restricted stock awards rather than secondary transfers from unrelated large holders. No recent sales by the filer are reported, which reduces immediate supply pressure. This notice is primarily a transparency and regulatory compliance event rather than material corporate news.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill 80 South 8th Street Suite 4000 Minneapolis MN 55402	11120	198000.00	18565033	08/28/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/31/2019	Restricted Stock Award	OptimizeRx Corporation			2084	10/01/2019	Restricted Stock Vest
Common	06/30/2019	Restricted Stock Award	OptimizeRx Corporation			2084	12/30/2019	Restricted Stock Vest
Common	09/30/2019	Restricted Stock Award	OptimizeRx Corporation			2084	03/30/2020	Restricted Stock Vest
Common	12/31/2019	Restricted Stock Award	OptimizeRx Corporation			2084	07/01/2020	Restricted Stock Vest
Common	03/31/2020	Restricted Stock Award	OptimizeRx Corporation			2784	10/01/2020	Restricted Stock Vest

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the OptimizeRx (OPRX) Form 144 propose to sell?

The filing proposes sale of 11,120 shares of common stock.

When is the approximate sale date listed on the Form 144 for OPRX?

The approximate date of sale is listed as 08/28/2025.

What is the aggregate market value of the shares proposed for sale in the OPRX filing?

The aggregate market value is reported as $198,000.

Through which broker will the OPRX shares be sold according to the filing?

The broker named is Merrill, 80 South 8th Street, Suite 4000, Minneapolis, MN 55402.

How were the shares being sold acquired according to the Form 144?

The shares were acquired as restricted stock awards from OptimizeRx between March 31, 2019 and March 31, 2020 with vesting/payment dates in 2019–2020.